Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Daudén E, de la Cueva P, Salgado-Boquete L, Llamas-Velasco M, Fonseca E, Pau-Charles I, Asensio D, Guilà M, Carrascosa JM; DIMESKIN 1 Study investigators. Daudén E, et al. Dermatol Ther (Heidelb). 2023 Jan;13(1):329-345. doi: 10.1007/s13555-022-00863-2. Epub 2022 Dec 1. Dermatol Ther (Heidelb). 2023. PMID: 36456890 Free PMC article.
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K; TRANSIT Investigators. Paul C, et al. Br J Dermatol. 2014 Feb;170(2):425-34. doi: 10.1111/bjd.12646. Br J Dermatol. 2014. PMID: 24116959 Free article. Clinical Trial.
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study.
Grau-Pérez M, Carretero G, Almeida P, Castro-González E, de-la-Rosa-Del-Rey MDP, González-Martín JM, Borrego L. Grau-Pérez M, et al. Among authors: carretero g. Cancer Causes Control. 2021 May;32(5):525-535. doi: 10.1007/s10552-021-01403-7. Epub 2021 Mar 1. Cancer Causes Control. 2021. PMID: 33646461
Correction to: The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study.
Grau-Pérez M, Carretero G, Almeida P, Castro-González E, de-la-Rosa-Del-Rey MDP, González-Martín JM, Borrego L. Grau-Pérez M, et al. Among authors: carretero g. Cancer Causes Control. 2021 Jul;32(7):791. doi: 10.1007/s10552-021-01437-x. Cancer Causes Control. 2021. PMID: 33913079 No abstract available.
110 results